// App-Quantinova.ai

: Long-Term Efficacy and Safety from the Copanlisib CHRONOS-1 Study in Patients with Relapsed or Refractory Indolent B-Cell Lymphoma

Researchers

Presenter

  • Martin Dreyling

Principal Investigators

  • Luigina Mollica

  • Sirpa Lepp

  • George A Follows

  • Georg Lenz

  • Won Seog Kim

  • Arnon Nagler

  • Panayiotis Panayiotidis

  • Judit Demeter

  • Muhit zcan

  • Marina Kosinova

  • Krimo Bouabdallah

  • Franck Morschhauser

  • Don Stevens

  • David Trevarthen

  • Liana Rodrigues

  • Florian Hiemeyer

  • MingLu Wang

  • Jose Garcia-Vargas

  • Barrett H. Childs

  • Pier Luigi Zinzani

Medical Centers

  • Klinikum der Universitat Munchen LMU, Medizinische Klinik und Poliklinik III, Munich, Germany

  • Humanitas Clinical and Research Center, Rozzano, Italy

  • Maisonneuve-Rosemont Hospital Research Center, Montreal, Canada

  • Helsinki University Hospital, Helsinki, Finland

  • Cambridge University Hospitals NHS Foundation Trust, Cambridge, United Kingdom

  • Translational Oncology, University Hospital Munster, Munster, Germany

  • Department of Pathology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of (South)

  • Chaim Sheba Medical Center-Tel Aviv University, Tel-Hashomer, Israel

  • National and Kapodistrian University of Athens, Athens, Greece

  • Semmelweis University, Budapest, Hungary

  • Ankara University, Ankara, Turkey

  • Kemerovo Region Regional Clinical Hospital, Kemerovo, Russia

  • Hematology, University Hospital of Bordeaux, Pessac, France

  • Hopital Claude Huriez, Lille, France

  • Norton Cancer Institute, Louisville, KY

  • Colorado Comprehensive Cancer Care, Englewood, CO

  • Bayer SA, Sao Paulo, Brazil

  • Bayer AG, Pharmaceuticals Division, Wuppertal, Germany

  • Syneos Health, Raleigh, NC

  • Bayer HealthCare Pharmaceuticals, Whippany, NJ

  • Institute of Hematology, University of Bologna, Bologna, Italy

Locations

  • Germany

  • Italy

  • Canada

  • Finland

  • United Kingdom

  • Republic of South Korea

  • Israel

  • Greece

  • Hungary

  • Turkey

  • France

  • United States

  • Brazil

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Follicular lymphoma

  • Hodgkin's Lymphoma

  • B cell lymphomas

  • Non‐Hodgkin Lymphoma

  • Lymphomas

Biomarkers

  • N/A

Drug/Treatment

  • Copanlisib

  • Rituximab

Outcome

  • N/A

Study Design

  • Fixed Dose

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved